FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions refers to an agent for suppression of progression, suppression of recurrence and/or treatment of a malignant growth. Disclosed is the use of the anti-allergin-1 antibody for improving immunity against a malignant growth in a patient with a solid malignant growth. Also disclosed is a method of increasing immunity against a solid malignant neoplasm and using the anti-allergin-1 antibody in preparing an agent increasing immunity for treating a solid malignant growth.
EFFECT: group of inventions provides higher immunity against a malignant growth.
27 cl, 14 dwg, 1 tbl, 12 ex
| Title |
Year |
Author |
Number |
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER |
2018 |
- Rietschel, Petra
- Lowy, Israel
|
RU2771759C2 |
| COMPOSITION FOR PREVENTING OR TREATING MALIGNANT TUMOUR, COMPRISING AGENT DESTROYING VESSELS, AND IMMUNE CONTROL POINT INHIBITOR |
2018 |
- Kim, Soo Jin
- Kim, U Ji
- Choi, Inhak
- Im, Suna
|
RU2738369C1 |
| COMPOSITIONS AND METHODS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER |
2016 |
- Chen, Lieping
- Wang, Jun
- Sun, Jingwei
|
RU2761980C2 |
| SEQUENTIAL CANCER TREATMENT USING 6-THIO-dG, CHECKPOINT INHIBITORS AND RADIATION THERAPY |
2021 |
- Shay, Jerry
- Fu, Yang-Xin
- Mender, Ilgen
- Zhang, Anli
|
RU2833475C1 |
| IL-4/IL-13 PATHWAY INHIBITORS FOR HIGHER EFFICACY IN TREATING MALIGNANT NEOPLASMS |
2020 |
- Liot, Caroline
- Kuhnert, Frank
|
RU2836467C2 |
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS |
2016 |
- Endryus Glen Ajan
- Chen Shikhao
- Di Petro Alessandra
- Fontana Dejvid
- Goldberg Zelanna
- Lin Chia-Yan
- Long Khua
- Martinoni Marsella
- Nujten Dmitrij Serzh Antuan
- Toll Aron Dejvid
- Vulfson Adrian
|
RU2766890C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT NEOPLASM |
2018 |
- Yoshida Tetsuya
- Kidani Yujiro
- Matsumoto Mitsunobu
- Kanazawa Takayuki
- Shinonome Satomi
- Hojo Kanji
- Ohkura Naganari
- Sakaguchi Shimon
- Tanaka Atsushi
- Wada Hisashi
- Kawashima Atsunari
- Nonomura Norio
|
RU2730984C1 |
| HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
- Khuan Khajchun'
|
RU2494107C2 |
| HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2013 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2599417C2 |
| COMBINATION OF TRIFLURIDINE/TIPIRACIL HYDROCHLORIDE, ANTITUMOR PLATINUM COMPLEX, AND MODULATOR OF CONTROL POINTS OF IMMUNE RESPONSE |
2018 |
- Abastado Jean-Pierre
- Amellal Nadia
- Bruno Alain
- Burbridge Michael Frank
- Cattan Valerie
- Leger Catherine
|
RU2778887C2 |
